Cardio-oncology & otherResearch article
Cardiovascular Toxicities of Bruton's Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukemia
- Narrative review
Study context
- Population
- Patients with chronic lymphocytic leukemia treated with BTK inhibitors
Main finding
As reported in the abstract
AF incidence with ibrutinib in chronic lymphocytic leukemia (CLL)
AF with ibrutinib, in up to
38%
Original publication
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia. JACC CardioOncol. Published 17 October 2023. doi:10.1016/j.jaccao.2023.09.002
Summarised from the published abstract; every number is checked against it